Akebia Therapeutics (AKBA) Revenue (2017 - 2026)

Akebia Therapeutics (AKBA) has reported Revenue for 10 consecutive years, with $49.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Revenue fell 21.36% year-over-year to $49.1 million in Q2 2026; TTM through Jun 2026 was $219.1 million, a 7.52% increase from a year earlier, with the FY2025 full-year figure at $236.2 million, up 47.46% from the prior year.
• Revenue was $49.1 million for Q2 2026 at Akebia Therapeutics, down from $53.5 million in the prior quarter.
• Over five years, Revenue peaked at $126.4 million in Q2 2022 and troughed at $32.6 million in Q1 2024.
• A 5-year average of $54.8 million and a median of $54.7 million in 2022 frame the typical range for Revenue.
• Across the five-year window, Revenue surged 138.82% in 2022 and tumbled 55.39% in 2023, its largest moves.
• Over 5 years, Revenue stood at $55.8 million in 2022, then rose by 0.74% to $56.2 million in 2023, then dropped by 17.26% to $46.5 million in 2024, then climbed by 23.93% to $57.6 million in 2025, then slipped by 14.74% to $49.1 million in 2026.
• The last three Revenue figures came in at $49.1 million (Q2 2026), $53.5 million (Q1 2026), and $57.6 million (Q4 2025), per Business Quant data.